Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 1/2019

01.10.2019 | Review

Thyroid hormone misuse and abuse

verfasst von: Victor J. Bernet

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects.
Literatur
1.
E.H. Hume, The contributions of China to the science and art of medicine. Science. 59, 345–350 (1924)CrossRefPubMed
2.
E.C. Kendall, The isolation in crystalline form of the compound containing iodin, which occurs in the thyroid. Its chemical nature and physiologic activity. JAMA 21(15), 2045–2046 (1983)CrossRef
3.
4.
5.
D. Schultheiss, J. Denil, U. Jonas, Rejuvenation in the early 20th century. Andrologia. 29(6), 351–355 (1997)CrossRefPubMed
6.
7.
K. Sterling, S. Refetoff, H.A. Selenkow, T3 thyrotoxicosis. Thyrotoxicosis due to elevated serum triiodothyronine levels. JAMA 27(4), 571–575 (1970)CrossRef
8.
Dietary Supplement Health and Education Act of 1994. Pub L N0. 103-417, 21 USC § 3419
9.
A.M. Abe, D.J. Hein, P.J. Gregory, Regulatory alerts for dietary supplements in Canada and the United States, 2005–13. Am. J. Health Syst. Pharm. 1(11), 966–971 (2015)CrossRef
10.
B.B. Timbo, M.P. Ross, P.V. McCarthy, C.T. Lin, Dietary supplements in a national survey: prevalence of use and reports of adverse events. J. Am. Diet. Assoc. 106(12), 1966–1974 (2006)CrossRefPubMed
11.
K.M. Wilson, J.D. Klein, T.S. Sesselberg, S.M. Yussman, D.B. Markow, A.E. Green, J.C. West, N.J. Gray, Use of complementary medicine and dietary supplements among U.S. adolescents. J. Adolesc. Health 38(4), 385–394 (2006)CrossRefPubMed
12.
P.A. Cohen, Hazards of hindsight-monitoring the safety of nutritional supplements. N. Engl. J. Med. 370(14), 1277–1280 (2014)CrossRefPubMed
13.
14.
C.E. Carvey, E.K. Farina, H.R. Lieberman, Confidence in the efficacy and safety of dietary supplements among United States active duty army personnel. BMC Complement. Alter. Med. 10(1), 182–194 (2012)
15.
A. Dickinson, J. Blatman, N. El-Dash, J.C. Franco, Consumer usage and reasons for using dietary supplements: report of a series of surveys. J. Am. Coll. Nutr. 33(2), 176–82 (2014)CrossRefPubMed
16.
17.
G.W. Neuberg, K.E. Stephenson, D.A. Sears, R.J. McConnell, Internet-enabled thyroid hormone abuse. Ann. Intern Med. 6(1), 60–61 (2009)CrossRef
18.
G.A. Bray, K.E. Melvin, I. Chopra, Effect of triiodothyronine on some metabolic responses of obese patients. Am. J. Clin. Nutr. 26(7), 715–721 (1973)CrossRefPubMed
19.
G.D. Braunstein, R. Koblin, M. Sugawara, A.E. Pekary, J.M. Hershman, Unintentional thyrotoxicosis factitia due to a diet pill. West J. Med. 145(3), 388–391 (1986)PubMedPubMedCentral
20.
C.T. Sawin, M.H. London, ‘Natural’ desiccated thyroid. A ‘health-food’ thyroid preparation. Arch. Intern. Med. 149(9), 2117–2118 (1989)CrossRefPubMed
21.
G.H. Daniels, P. Sluss, Pure T3-thyrotoxicosis from a Mexican weight losssupplement. Endocr. Pract. 19(3), 559–560 (2013)PubMed
22.
G.Y. Kang, J.R. Parks, B. Fileta, A. Chang, M.M. Abdel-Rahim, H.B. Burch, V.J. Bernet, Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid 23(10), 1233–1237 (2013)CrossRefPubMed
23.
H.K. Akturk, A.M. Chindris, J.M. Hines, R.J. Singh, V.J. Bernet, Over-the-counter “adrenal support” supplements contain thyroid and steroid-based adrenal hormones. Mayo Clin. Proc. 933, 284–290 (2018)CrossRef
24.
C.D. Seger, X. He, L.E. Braverman, M.W. Yeh, V.J. Bernet, R.J. Singh, C.M. Rhee, A.M. Leung, Negligible thyroid hormone content present in nonprescription U.S. Weight Loss Products. Thyroid 27(2), 300–301 (2017)CrossRefPubMedPubMedCentral
25.
G. Brenta, S. Danzi, I. Klein, Potential therapeutic applications of thyroid hormone analogs. Nat. Clin. Pr. Endocrinol. Metab. 3(9), 632–640 (2007)CrossRef
26.
G. Radetti, L. Persani, G. Molinaro, D. Mannavola, D. Cortelazzi, V.K. Chatterjee, P. Beck-Peccoz, Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid. 7(5), 775–778 (1997)CrossRefPubMed
27.
M. Moreno, P. de Lange, A. Lombardi, E. Silvestri, A. Lanni, F. Goglia, Metabolic effects of thyroid hormone derivatives. Thyroid. 18(2), 239–253 (2008)CrossRefPubMed
28.
B.A. Bauer, P.L. Elkin, D. Erickson, G.G. Klee, M.D. Brennan, Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. Mayo Clin. Proc. 77(6), 587–590 (2002)CrossRefPubMed
29.
Food and Drug Administration. FDA warns against consuming dietary supplements containing tiratricol (National Press Office: Talk Paper, Rockville, MD, 1999)
30.
J. Cohen-Lehman, M.M. Charitou, I. Klein, Tiratricol-induced periodic paralysis: a review of nutraceuticals affecting thyroid function. Endocr. Pract. 17(4), 610–615 (2011)CrossRefPubMed
31.
Y.C. Chen, J.T. Fang, C.T. Chang, H.H. Chou, Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren. Fail. 23(1), 139–142 (2001)CrossRefPubMed
32.
M.C. Scally, A. Hodge, A report of hypothyroidism induced by an over-the-counter fat loss supplement (Tiratricol). Int J. Sport Nutr. Exerc Metab. 13(1), 112–116 (2003)CrossRefPubMed
33.
34.
K.M. Allen, V.B. Crawford, J.V. Conaglen, M.S. Elston, Case report: clues to the diagnosis of an unsuspected massive levothyroxine overdose. CJEM 17(6), 692–698 (2015)CrossRefPubMed
35.
B. Nygaard, E.A. Saedder, K. Dalhoff, M. Wikkelsoe, G. Jürgens, Levothyroxine poisoning—symptoms and clinical outcome. Basic Clin. Pharm. Toxicol. 117(4), 280–285 (2015)
36.
S. Bhasin, W. Wallace, J.B. Lawrence, M. Lesch, Sudden death associated with thyroid hormone abuse. Am. J. Med. 71(5), 887–890 (1981)CrossRefPubMed
37.
J.B. Mowry, D.A. Spyker, L.R. Cantilena Jr, J.E. Bailey, M. Ford, 2012 annual report of the American association of poison control centers’ national poison data system (NPDS): 30th annual report. Clin. Toxicol. (Philos.). 51(10), 949–1229 (2013)CrossRef
38.
J.H. Cohen 3rd, S.H. Ingbar, L.E. Braverman, Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr. Rev. 10(2), 113–124 (1989)CrossRefPubMed
39.
Plummer H. Tr. Assn. Am. Phys. 46, 171 (1931)
40.
J.F. Dymling, D.V. Becker, Occurrence of hyperthyroidism in patients receiving thyroid hormone. J. Clin. Endocrinol. Metab. 27, 1487–1491 (1967)CrossRefPubMed
41.
C.W. Hedberg, D.B. Fishbein, R.S. Janssen, B. Meyers, J.M. McMillen, K.L. MacDonald, K.E. White, L.J. Huss, E.S. Hurwitz, J.R. Farhie, J.L. Simmons, L.E. Braverman, An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N. Engl. J. Med. 16(316), 993–998 (1987)CrossRef
42.
M.S. Parmar, C. Sturge, Recurrent hamburger thyrotoxicosis. CMAJ 2(5), 415–417 (2003)
43.
N.D. Brayshaw, D.D. Brayshaw, Thyroid hypofunction in premenstrual syndrome. N. Engl. J. Med. 4(23), 1486–1487 (1986)
44.
T.F. Nikolai, G.M. Mulligan, R.K. Gribble, P.G. Harkins, P.R. Meier, R.C. Roberts, Thyroid function and treatment in premenstrual syndrome. J. Clin. Endocrinol. Metab. 70(4), 1108–1113 (1990)CrossRefPubMed
45.
W.F. Young Jr, C.A. Gorman, N.S. Jiang, D. Machacek, I.D. Hay, L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect. Clin. Pharm. Ther. 36(6), 781–787 (1984)CrossRef
46.
X. Zhou, A.V. Ravindran, B. Qin, C. Del Giovane, Q. Li, M. Bauer, Y. Liu, Y. Fang, T. da Silva, Y. Zhang, L. Fang, X. Wang, P. Xie, Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J. Clin. Psychiatry 76(4), e487–e498 (2015)CrossRefPubMed
47.
R. Aronson, H.J. Offman, R.T. Joffe, C.D. Naylor, Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry 53(9), 842–848 (1996)CrossRefPubMed
48.
T. Parmentier, P. Sienaert, The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. J. Affect Disord. 15(229), 410–414 (2018)CrossRef
49.
50.
L. Wartofsky, K.D. Burman, Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr. Rev. 3(2), 164–217 (1982)CrossRefPubMed
51.
R.A. Becker, G.M. Vaughan, M.G. Ziegler, L.G. Seraile, I.W. Goldfarb, E.H. Mansour, W.F. McManus, B.A. Pruitt Jr, A.D. Mason Jr., Hypermetabolic low triiodothyronine syndrome of burn injury. Crit. Care Med. 10(12), 870–875 (1982)CrossRefPubMed
52.
D. Novitzky, D.K. Cooper, C.I. Barton, A. Greer, J. Chaffin, J. Grim, N. Zuhdi, Triiodothyronine as an inotropic agent after open heart surgery. J. Thorac. Cardiovasc Surg. 98(5 Pt 2), 972–977 (1989)PubMed
53.
G.A. Brent, J.M. Hershman, Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J. Clin. Endocrinol. Metab. 63(1), 1–8 (1986)CrossRefPubMed
54.
S. Lee, A.P. Farwell, Euthyroid sick syndrome. Compr. Physiol. 15(2), 1071–1080 (2016)CrossRef
55.
56.
57.
A. Bains, A.J. Brosseau, D. Harrison, Iatrogenic thyrotoxicosis secondary to compounded liothyronine. Can. J. Hosp. Pharm. 68(1), 57–59 (2015)PubMedPubMedCentral
58.
V. Ioos, V. Das, E. Maury, J.L. Baudel, J. Guéchot, B. Guidet, G. Offenstadt, A thyrotoxicosis outbreak due to dietary pills in Paris. Ther. Clin. Risk Manag. 4(6), 1375–1379 (2008)PubMedPubMedCentral
Metadaten
Titel
Thyroid hormone misuse and abuse
verfasst von
Victor J. Bernet
Publikationsdatum
01.10.2019
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02045-1

Weitere Artikel der Ausgabe 1/2019

Endocrine 1/2019 Zur Ausgabe

Review

T4 + T3 combination therapy: any progress?

Original Article

The isolation of thyroxine (T4), the discovery of 3,5,3’-triiodothyronine (T3), and the identification of the deiodinases that generate T3 from T4: An historical review

Review

Thyroid hormone therapy of hypothyroidism in pregnancy

Review

Thyroid hormone therapy in differentiated thyroid cancer

Mini Review

Novel thyroid hormones

Review

Thyroid hormone therapy for subclinical hypothyroidism

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise